Preserving Muscle Mass on GLP-1s: A Practical Guide for Singaporeans

The rise of GLP-1 receptor agonists like semaglutide and tirzepatide has transformed obesity management in Singapore, offering profound weight loss previously only seen with bariatric surgery. However, as the focus shifts from kilograms lost to the quality of weight loss, a growing concern has emerged: are we losing healthy skeletal muscle alongside fat?

Why does lean/muscle mass loss happen?

While a reduction in lean mass is a natural, adaptive outcome during any significant weight loss, it does not automatically mean you are suffering from muscle wasting or sarcopenia. In fact, clinical trials show that fat loss—particularly harmful visceral and abdominal fat—dominates weight loss on GLP-1 therapies.

The key is ensuring your strength, physical function, bone health, and nutrient intake remain fully protected. Lean mass loss during GLP-1 or dual-incretin therapy occurs through four primary shared mechanisms:

• Sustained Energy Deficit: GLP-1 therapies reduce dietary energy intake by approximately 16% to 39%. Any significant calorie reduction reduces overall body mass and the mechanical/metabolic demands placed on the body, causing adaptive tissue remodeling.
• Reduced Protein Intake: Gastrointestinal side effects (nausea, vomiting, constipation, early satiety, food aversion) lower total food intake and narrow tolerated foods. As a result, protein intake often falls below the threshold needed for muscle protein synthesis.
• ​Reduced Mechanical Loading: Losing total body weight reduces the everyday gravitational and mechanical load on muscles and bones, leading to loss of tissue unless counteracted by resistance exercise.
• Adaptive Tissue Remodeling: Reductions in non-contractile components of the muscles—such as fat, intramuscular lipid, fluid, glycogen stores, and tissue inflammation—can lower measured lean mass while actually improving muscle quality and insulin sensitivity.

Does it happen to everyone?

No, not in a uniform or pathological way. While a smaller, proportional reduction in lean soft tissue or fat-free mass is expected during major weight loss across most individuals, fat loss remains predominant across the population. Significant or clinically problematic muscle/functional deterioration is not universal and depends heavily on individual risk factors:

• High-Risk Individuals: Older adults, people with type 2 diabetes, individuals with low baseline physical activity, those with pre-existing sarcopenic obesity, and patients experiencing persistent gastrointestinal symptoms/poor protein intake are significantly more vulnerable to unhealthier tissue loss.
• ​Low-Risk Individuals: Patients who maintain adequate protein intake, preserve dietary variety, and participate in structured resistance exercise can lose substantial fat mass while stabilizing or improving muscle function and composition.

Is it dose dependent?

Higher doses achieve greater overall weight loss (for example, tirzepatide weight loss was roughly 15–21% depending on the dose in SURMOUNT-1). Because higher doses produce greater energy deficits, greater appetite suppression, and larger total kilograms lost, they consequently lead to larger absolute amounts of lean tissue loss in kilogram terms, even when the fat-to-lean loss ratio remains stable.

Which medicine is more likely: tirzepatide or semaglutide?

Neither medicine seems to selectively depletes lean tissue beyond what is expected for their respective degree of weight loss. However, their profiles show differences due to overall weight loss magnitude:

• Semaglutide (STEP 1 DXA Substudy): Reduced total fat mass by 19.3%, visceral fat by 27.4%, and lean body mass by 9.7%. Overall, the relative proportion of total body weight made up of lean mass actually increased by 3.0 percentage points.
• Tirzepatide (SURMOUNT-1 DXA Substudy): Led to greater absolute weight loss. About 74% (15.9 kg) of total weight loss was fat mass, and 26% (5.6 kg) was lean soft tissue.
• ​Comparison: Tirzepatide achieves greater total weight loss than semaglutide. Because tirzepatide produces larger absolute weight reductions, it results in a higher absolute quantity (in kilograms) of lean soft tissue lost, making tissue preservation particularly relevant for high-risk phenotypes taking it. However, meta-analyses demonstrate that across all GLP-1 receptor agonists and dual agonists, lean loss remains a minority of total weight change and relative lean mass generally does not deteriorate.

Is there an optimal GLP-1 treatment duration?

While there is no "optimal" treatment duration, it is important to understanding:

• Chronic Disease Management: Obesity is a chronic disease requiring sustained management; long-term extension studies confirm that continued therapy is required to sustain clinically meaningful reductions.
• Consequences of Discontinuation: When GLP-1 therapy is stopped, rapid weight regain occurs. Patients regain an average of 0.4 kg per month after stopping, projecting back toward baseline body weight within ~1.7 years, accompanied by full reversal of cardiometabolic gains.
• Phase-Based Monitoring: Rather than stopping therapy, care should be adapted across treatment phases—focusing on symptom control and protein safeguarding during titration, muscle/bone preservation during active loss, and preventing diet quality deterioration during long-term maintenance.

How to optimize my body composition?

Here is how you can optimize your body composition and safeguard your musculoskeletal health while taking GLP-1 medications in Singapore.

Prioritize Protein (Even When You Don't Feel Like Eating)

GLP-1 medications work by suppressing appetite, delaying gastric emptying, and inducing early satiety. While effective for losing weight, this drastically reduces total dietary intake—often leading to inadequate daily protein. Studies show that fewer than half of patients on GLP-1s meet baseline protein requirements without deliberate effort.

• Target Intake: Aim for 1.2 to 1.5 grams of protein per kilogram of body weight daily during active weight loss.
• Distribute Across Meals: Avoid loading all your protein into dinner. Distribute protein evenly across breakfast, lunch, and dinner to maximize muscle protein synthesis throughout the day.
• ​Singapore-Friendly Options: Focus on lean, nutrient-dense protein sources suitable for local palates: - ​Steamed chicken breast (e.g., from chicken rice stalls, hold off the gravy) - ​Tau kway (firm tofu), un-fried tempeh - ​Fish soup (clear broth, sliced fish without milk) ​- Eggs, Greek yogurt, and low-sugar soy milk
• ​When Appetite is Low: If solid food feels unappealing due to mild nausea, turn to liquid protein sources like whey or plant-based protein shakes.

Manage Side Effects and Protect Nutrient Density

Because total food intake drops significantly on GLP-1s, every meal must be nutritionally dense. Avoid ultra-processed foods. Gastrointestinal side effects like nausea, early satiety, and constipation can inadvertently lead to poor food choices or severe micronutrient gaps (such as lower levels of iron, calcium, vitamin D, and B vitamins).

• Eat Protein First: When sitting down for a meal, eat your protein source first before moving to carbohydrates or vegetables to ensure you hit your protein goals before feeling full.
• Smaller, Frequent Eating: If nausea strikes during dose escalation, eat smaller portions spaced throughout the day rather than forcing large meals.
• ​Hydration & Fiber: Drink plenty of fluids between meals, and maintain a steady intake of soluble fiber (e.g., oats, leafy greens, chia seeds) to combat constipation without over-bulking the stomach.

Progressive Resistance Training is Non-Negotiable

Relying solely on diet or aerobic exercise (like jogging or walking) during rapid weight loss increases the likelihood of losing lean mass and bone mineral density. Progressive resistance training provides the essential mechanical load required to signal your body to hold onto skeletal muscle.

• Minimum Effective Dose: Engage in structured resistance exercise 2 to 3 times per week targeting major muscle groups.
• ​You don't need a high-end gym membership to start. Incorporate bodyweight exercises (push-ups, squats, lunges), resistance band workouts, or utilize fitness corners in your local HDB estate or ActiveSG gym.
• ​Combine Modalities: Pair strength workouts with light-to-moderate aerobic activity (like brisk walking along park connectors) to support cardiovascular health while preserving physical function.

Track Function and Muscle Quality, Not Just the Scale

Dropping weight on the bathroom scale does not tell the full story. Rather than worrying exclusively about total weight lost, track functional markers to gauge your muscle health:

• Monitor everyday strength—are you able to carry heavy grocery bags from the supermarket, climb stairs easily, or rise from a chair without using your hands?
• ​Body Composition Tracking: If tracking progress beyond weight is desired, simple bioelectrical impedance analysis (BIA) scans at local healthcare or fitness facilities can help track relative fat versus fat-free mass over time. Remember that strength and mobility matter far more than a single number on an imaging scan.

Evidence Strength: This review synthesizes direct trial data from major GLP-1 and dual GIP/GLP-1 clinical programs (including STEP and SURMOUNT), imaging substudies, and meta-analyses, alongside established clinical nutrition and exercise guidelines evaluated via an evidence-weighted framework. Final Rating: ★★★★☆

Source: Read the full study